1. Home
  2. GSHR vs ESPR Comparison

GSHR vs ESPR Comparison

Compare GSHR & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSHR
  • ESPR
  • Stock Information
  • Founded
  • GSHR 2024
  • ESPR 2008
  • Country
  • GSHR United States
  • ESPR United States
  • Employees
  • GSHR N/A
  • ESPR N/A
  • Industry
  • GSHR
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSHR
  • ESPR Health Care
  • Exchange
  • GSHR NYSE
  • ESPR Nasdaq
  • Market Cap
  • GSHR 205.8M
  • ESPR 220.0M
  • IPO Year
  • GSHR 2025
  • ESPR 2013
  • Fundamental
  • Price
  • GSHR $10.15
  • ESPR $1.51
  • Analyst Decision
  • GSHR
  • ESPR Buy
  • Analyst Count
  • GSHR 0
  • ESPR 6
  • Target Price
  • GSHR N/A
  • ESPR $6.50
  • AVG Volume (30 Days)
  • GSHR 345.0
  • ESPR 4.8M
  • Earning Date
  • GSHR 01-01-0001
  • ESPR 08-05-2025
  • Dividend Yield
  • GSHR N/A
  • ESPR N/A
  • EPS Growth
  • GSHR N/A
  • ESPR N/A
  • EPS
  • GSHR N/A
  • ESPR N/A
  • Revenue
  • GSHR N/A
  • ESPR $259,574,000.00
  • Revenue This Year
  • GSHR N/A
  • ESPR $5.15
  • Revenue Next Year
  • GSHR N/A
  • ESPR N/A
  • P/E Ratio
  • GSHR N/A
  • ESPR N/A
  • Revenue Growth
  • GSHR N/A
  • ESPR 12.99
  • 52 Week Low
  • GSHR $9.97
  • ESPR $0.69
  • 52 Week High
  • GSHR $10.50
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • GSHR N/A
  • ESPR 71.94
  • Support Level
  • GSHR N/A
  • ESPR $1.13
  • Resistance Level
  • GSHR N/A
  • ESPR $2.08
  • Average True Range (ATR)
  • GSHR 0.00
  • ESPR 0.15
  • MACD
  • GSHR 0.00
  • ESPR 0.03
  • Stochastic Oscillator
  • GSHR 0.00
  • ESPR 41.84

About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A

Gesher Acquisition Corp II is a blank check company.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: